Opendata, web and dolomites

ClearPlasma SIGNED

ClearPlasma is an innovative medical device that enhances coagulation properties for improved treatment of excessive bleeding.

Total Cost €


EC-Contrib. €






Project "ClearPlasma" data sheet

The following table provides information about the project.


Organization address
address: WADI EL HAJ 13
postcode: 1600101
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PLAS-FREE LTD IL (NAZARETH) coordinator 50˙000.00


 Project objective

Each year, almost 2 million people die from haemorrhaging, or blood loss. Massive blood loss can occur upon: Trauma, Surgery, Childbirth, Disseminated Intravascular Coagulation (DIC), Gastrointestinal Bleeding, etc. In all of these cases, there is an urgent need for efficient plasma transfusion to halt the bleeding. However, recent studies have shown that regular plasma fails to stop massive bleeding, while other treatments show low efficacy and increased mortality risk. ClearPlasma is an innovative filtration system that modifies human plasma to improve the treatment of massive bleeding and bleeding disorders. By extracting plasminogen, an important protein responsible for dissolving blood clots, ClearPlasma enhances coagulation and favours haemostasis, thus reducing bleeding of 55%. This translates into the opportunity to reduce up to 45% the units of plasma needed during transfusion, hence reducing treatment costs. ClearPlasma is a disposable filter that can be incorporated in current Apheresis systems thus not affecting common clinical practices. ClearPlasma addresses the Global Blood Transfusion Diagnostics Market, which was valued at approximately € 3.2bn in 2017, and is expected to reach around € 4.7bn by 2024, growing at a CAGR of 6.2% between 2018 and 2024. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of ClearPlasma and its market uptake.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLEARPLASMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CLEARPLASMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More